Estimation of Myocardial Iron Overload by 3 Tesla MRI in HFE Hereditary Haemochromatosis

NCT02099214 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2017-10-20

No results posted yet for this study

Summary

Hereditary haemochromatosis (HHC) is a frequent disease in Brittany (5 to 7‰), responsible first for biological disorder in blood iron parameters and minor clinical disorders, before evolving to potential life-threatening consequences such as diabetes, liver cirrhosis and congestive heart failure.

The improvement of screening and treatments made those severe affections rare enough not to evaluate myocardial iron overload a systematic part of the starting check-up. Nonetheless this myocardial iron overload might have severe implications on cardiac function on a long term basis.

A single trial was conducted on limited number of patients with 1.5 Tesla MRI, which showed a myocardial iron overload (defined by a myocardium T2\* value \<20ms) in 19% of the subjects.

The main objective of this study is to precisely estimate cardiac iron overload in treatment naive patients with newly diagnosed HFE hereditary haemochromatosis with a 3 Tesla MRI, more sensitive than the 1.5 Tesla one, in order to later appreciate its correlation with cardiac morbidity in HHC.

Conditions

  • Myocardial Iron Overload
  • HFE-Associated Hereditary Hemochromatosis

Interventions

DEVICE

3Tesla cardiac MRI

DEVICE

Electrocardiogram (EKG)

BIOLOGICAL

Iron and cardiac markers

Serum iron, serum transferrin, transferrin saturation, serum ferritin, NT-proBNP

BIOLOGICAL

Pregnancy test

Beta-hCG

DEVICE

Echocardiography at rest

Transthoracic echocardiograph

BIOLOGICAL

Urinary pregnancy test

DEVICE

3Tesla abdominal MRI

Sponsors & Collaborators

  • Rennes University Hospital

    lead OTHER

Principal Investigators

  • Erwan DONAL, MD, PhD · Rennes University Hospital - Service de cardiologie et maladies vasculaires

  • Bruno LAVIOLLE, MD, PhD · Rennes University Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-11-05
Primary Completion
2017-10-18
Completion
2017-10-18

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02099214 on ClinicalTrials.gov